

Halogen bonding enhances affinity for 5-HT₇R in a series of N-[2-(dimethylamino)ethyl]-N-(2-phenylethyl)anilines

Jakub Staroń, Rafał Kurczab, Dawid Warszycki, Grzegorz Satała, Ryszard Bugno, Adam Hogendorf, Andrzej J. Bojarski

Department of Medicinal Chemistry, Institute of Pharmacology Polish Academy of Sciences
12 Smętna Street, 31-343 Cracow, Poland, staron@if-pan.krakow.pl

Background

Halogen bonds (XB) are specialized non-covalent interactions known to chemists since XIX century, but only recently they were recognized as important in biological molecules.¹ According to IUPAC definition, halogen bond is "a net attractive interaction between an electrophilic region associated with a halogen atom in a molecular entity and a nucleophilic region in another, or the same, molecular entity".² In biological targets the XB can involve carbonyl oxygen, hydroxyl groups of serine, threonine and tyrosine, carboxylate groups of aspartic and glutamic acid, sulphur of cysteine and methionine and the π -surfaces of phenylalanine, tyrosine, histidine and tryptophane.

Within the serotonergic system, 5-HT₇, the last identified serotonin receptor, is one of the most valuable drug targets.³ Experiments using animal models have shown that the receptor is involved in many physiological processes, i.e. regulation of body temperature, smooth muscle relaxation of cerebral arteries, circadian rhythm, learning and memory, as well as pathophysiological processes such as mood disorders, anxiety, inflammatory processes in the CNS, schizophrenia and pain.⁴ 5-HT₇R antagonists have been proposed as potential drugs targeting depression.⁵ It was established that 5-HT₇ blockade can induce promnesic effects implicating the possibility to develop atypical procognitive antidepressants.⁶

Molecular modelling

The QM-Polarized Ligand Docking (QPLD)⁶ in the Schrödinger Suite was used to dock all synthesized compounds 5-HT₇ homology models. Next, QSite was used to perform a single-point energy calculation for each obtained L-R complex, treating the ligand with ab initio (B3LYP/6-31G*) and the receptor with the MM (OPLS-2005) level of theory. Partial atomic charges were calculated using the electrostatic potential fitting method. Glide was subsequently applied to re-dock the ligand using each of the ligand charge sets calculated by QSite, and the QPLD algorithm was used to return the most energetically favourable poses. For a particular ligand, the Generalized-Born/Surface Area continuum solvent model was used to estimate ΔG values to select the correct poses between possible binding conformations. To visualize (plotting interaction spheres) the possible contribution of halogen bonding to the resulting ligand-receptor complexes, the Halogen Bonding Webserver was used (access 1.12.2015, <http://www.halogenbonding.com/>).




Figure 1. Representative L-R complexes (top scores based on ΔG) of unsubstituted compound **1** (orange) and 4-chloro substituted **14** (yellow). Amino acids that were selected as crucial for the binding of the presented compounds are shown as sticks. A basic nitrogen atom forms a charge-assisted hydrogen bond with aspartic acid Asp3.32, an aniline aromatic ring interacts with Phe6.52. The $\Delta\Delta G$ [kcal/mol] value shows the difference between ΔG of complexes of a particular compound (**14**) and an unsubstituted analogue **1**.




Figure 2. Representative L-R complexes (top scores based on ΔG) of a 4-methyl substituted compound **5** (cyan) and 4-methoxy substituted **7** (magenta).





Figure 3. A superposition of the top scored poses of 4-Cl (**4m**, yellow) and 3-Cl (**4f**, blue) derivatives against putative halogen binding pocket interaction spheres. The higher binding energy value for 3-Cl than for 4-Cl derivatives illustrates the highly directional nature of the identified halogen bond interaction. The methodology applied has been described by Wilcken et al.⁷

Synthesis



Binding affinity

Radioligand binding assays were used to determine the affinity and selectivity profiles of the synthesized compounds for human serotonin 5-HT_{1A}R, 5-HT_{2A}, 5-HT₆R, 5-HT₇R and D₂L_R, which were stably expressed in HEK293 cells.

Table 1. Binding affinities of the synthesized compounds

Cmpd.	n	R1	Substitution				K _i [nM]				
			R2	R3	R4	5-HT _{1A}	5-HT _{2A}	5-HT ₆	5-HT ₇	D ₂	
1	1	Me	H	H	H	1682	233	63	121	476	
2	1	Et	H	H	H	7614	128	51	205	266	
3	2	Me	H	H	H	4486	228	67	623	55	
4	1	Me	H	H	F	5707	58	23	31	37	
5	1	Me	H	H	Me	482	70	25	10	33	
6	1	Me	H	H	CF ₃	5341	809	61	30	274	
7	1	Me	H	H	OMe	>10000	863	234	141	1147	
8	1	Me	H	Me	H	605	777	264	2253	n.d.	
9	2	Me	H	H	F	8969	27	38	38	80	
10	1	Me	H	F	H	>10000	312	64	748	594	
11	1	Me	Cl	H	Cl	>10000	472	597	387	1176	
12	1	Me	H	OMe	H	>10000	721	355	4512	1738	
13	2	Me	H	H	Me	2140	204	83	24	108	
14	1	Me	H	H	Cl	5960	212	24	4	153	
15	1	Me	Me	H	H	>10000	348	380	1040	n.d.	
16	1	Me	naphthyl	H	H	137	4749	137	4749	2037	
17	1	Me	H	F	F	>10000	79	21	114	n.d.	
18	1	Me	H	H	Br	n.d.	295	90	19	505	
19	1	Me	H	H	I	n.d.	372	79	10	691	
20	1	Me	Me	H	Me	n.d.	518	347	597	1751	
21	1	Me	H	Cl	H	n.d.	311	150	353	675	

n.d. – not determined

Bibliography

- Hardegger, L. A.; et al., *Angew. Chem. Int. Ed.* **2011**, *50*, 314–318.
- Desiraju, G. R.; et al., *Pure Appl. Chem.* **2013**, *85*, 1711–1713.
- Hedlund P. B. and Sutcliffe J. G., *Trends Pharmacol. Sci.*, 2004, **25**, 481–486.
- Matthys A., et al., *Mol. Neurobiol.*, 2011, **43**, 228–53.
- Wesotowska A., et al., *Neuropharmacology*, 2006, **51**, 578–86.
- Gasbarri A. and Pompili A., *Rev. Neurosci.*, 2014, **25**, 311–23.
- Wilcken R., et al., *Comp. Aided Mol. Des.*, 2012, **26**, 935–945.



Acknowledgements

The study was partially supported by the Polish-Norwegian Research Programme operated by the National Centre for Research and Development under the Norwegian Financial Mechanism 2009–2014 in the frame of the Project PLATFORMex (Pol-Nor/198887/73/2013) and by the National Science Center Grant No DEC-2014/15/D/NZ7/01782.